Biotest AG logo

BIO3 - Biotest AG News Story

€29.6 -0.2  -0.7%

Last Trade - 4:36pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.02bn
Enterprise Value £1.35bn
Revenue £419.7m
Position in Universe 387th / 1046

BRIEF-Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin

Tue 27th February, 2018 9:30am
Feb 27 (Reuters) - BIOTEST AG  BIOG.DE : 
    * DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT 
GUIDANCE 
    * FY REVENUE 378.1 MILLION EUR 
    * MAIN REASON FOR DECLINE IN REVENUE WAS RECALL OF HUMAN 
ALBUMIN 
    * FY  EBIT GUIDANCE WAS REACHED WITH EUR 18 MILLION 
    * 2017 REVENUE OF EUR 378.1 MILLION IN CONTINUING 
OPERATIONS, 
COMPARED TO EUR 408.0 MILLION IN PREVIOUS YEAR 
    * ONE-OFF EXPENSES IN AMOUNT OF EUR 37.7 MILLION HAD A 
NEGATIVE 
IMPACT ON EBIT OF CONTINUING OPERATIONS 
    * EBIT IN CONTINUING OPERATIONS AMOUNTED TO EUR -9.3 MILLION 
IN 
2017 AFTER EUR 35.2 MILLION IN PREVIOUS YEAR 
 
Source text for Eikon:  ID:nEQ5sdkTWa  
Further company coverage:  BIOG.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.